Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 2/20 | 0.42 |
| ▸ | FERMT2 | Q96AC1 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 2/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.33 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18544879 | 0.79 | GAK (0.44) | GAKNR4A2SOS2CCNCCDK8 | |
| Iodide SCHEMBL11565912 | 0.78 | GAK (0.43) | GAKNR4A2SOS2CCNCCDK8 | |
| SCHEMBL13283952 | 0.76 | CCR1 (0.48) | GAKNR4A2SOS2CCNCCDK8 | |
| SCHEMBL4355081 | 0.76 | NR4A2 (0.61) | FERMT2NR4A2SOS2CYP1A2GAA | |
| SCHEMBL1618081 | 0.76 | NR4A2 (0.43) | GAKFERMT2NR4A2SOS2APP | |
| SCHEMBL8601956 | 0.76 | GAK (0.42) | GAKTGFBR1NR4A2SOS2CCNC | |
| SCHEMBL3319590 | 0.76 | NR4A2 (0.61) | GAKFERMT2NR4A2SOS2CCNC | |
| SCHEMBL19878153 | 0.76 | ALK (0.50) | GAKFERMT2CYP1A2MAPT | |
| SCHEMBL20847698 | 0.76 | HTR1A (0.54) | FERMT2TGFBR1PARP1CYP1A2HTR1A | |
| SCHEMBL500930 | 0.76 | AR (0.42) | GAKNR4A2SOS2CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618986-B2 | Method of treating latent tuberculosis | EVANSTON NORTHWESTERN HEALTHCARE (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080076797-A1 | Method of Treating Latent Tuberculosis | EVANSTON NORTHWESTERN HEALTHCARE (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076797-A1 | Method of Treating Latent Tuberculosis | SDHA, NDUFB7, DUT | GAK 1616/4885FERMT2 3812/4885TGFBR1 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.